Literature DB >> 30691643

Investigation of the cyclic oligoadenylate signaling pathway of type III CRISPR systems.

Christophe Rouillon1, Januka S Athukoralage1, Shirley Graham1, Sabine Grüschow1, Malcolm F White2.   

Abstract

Type III CRISPR effector complexes utilize a bound CRISPR RNA (crRNA) to detect the presence of RNA from invading mobile genetic elements in the cell. This RNA binding results in the activation of two enzymatic domains of the Cas10 subunit-the HD nuclease domain, which degrades DNA, and PALM/cyclase domain. The latter synthesizes cyclic oligoadenylate (cOA) molecules by polymerizing ATP, and cOA acts as a second messenger in the cell, switching on the antiviral response by activating host ribonucleases and other proteins. In this chapter, we focus on the methods required to study the biochemistry of this recently discovered cOA signaling pathway. We cover protein expression and purification, synthesis of cOA and its linear analogues, kinetic analysis of cOA synthesis and cOA-stimulated ribonuclease activity, and small molecule detection and identification with thin-layer chromatography and mass spectrometry. The methods described are based on our recent studies of the type III CRISPR system in Sulfolobus solfataricus, but are widely applicable to other type III systems.
© 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CARF; CRISPR type III; Csm6; Csx1; Cyclic oligoadenylate; HEPN; MazEF; Ribonuclease; Ring nuclease

Mesh:

Substances:

Year:  2019        PMID: 30691643     DOI: 10.1016/bs.mie.2018.10.020

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  11 in total

1.  Cyclic nucleotide-induced helical structure activates a TIR immune effector.

Authors:  Gaëlle Hogrel; Abbie Guild; Shirley Graham; Hannah Rickman; Sabine Grüschow; Quentin Bertrand; Laura Spagnolo; Malcolm F White
Journal:  Nature       Date:  2022-08-10       Impact factor: 69.504

2.  A Type III CRISPR Ancillary Ribonuclease Degrades Its Cyclic Oligoadenylate Activator.

Authors:  Januka S Athukoralage; Shirley Graham; Sabine Grüschow; Christophe Rouillon; Malcolm F White
Journal:  J Mol Biol       Date:  2019-05-06       Impact factor: 5.469

3.  Cyclic oligoadenylate signalling mediates Mycobacterium tuberculosis CRISPR defence.

Authors:  Sabine Grüschow; Januka S Athukoralage; Shirley Graham; Tess Hoogeboom; Malcolm F White
Journal:  Nucleic Acids Res       Date:  2019-09-26       Impact factor: 16.971

4.  Structure and mechanism of a Type III CRISPR defence DNA nuclease activated by cyclic oligoadenylate.

Authors:  Stephen A McMahon; Wenlong Zhu; Shirley Graham; Robert Rambo; Malcolm F White; Tracey M Gloster
Journal:  Nat Commun       Date:  2020-01-24       Impact factor: 14.919

5.  An RNA Repair Operon Regulated by Damaged tRNAs.

Authors:  Kevin J Hughes; Xinguo Chen; A Maxwell Burroughs; L Aravind; Sandra L Wolin
Journal:  Cell Rep       Date:  2020-12-22       Impact factor: 9.423

Review 6.  The Cyclic Oligoadenylate Signaling Pathway of Type III CRISPR-Cas Systems.

Authors:  Fengtao Huang; Bin Zhu
Journal:  Front Microbiol       Date:  2021-01-20       Impact factor: 5.640

7.  Regulation of the RNA and DNA nuclease activities required for Pyrococcus furiosus Type III-B CRISPR-Cas immunity.

Authors:  Kawanda Foster; Sabine Grüschow; Scott Bailey; Malcolm F White; Michael P Terns
Journal:  Nucleic Acids Res       Date:  2020-05-07       Impact factor: 16.971

8.  The dynamic interplay of host and viral enzymes in type III CRISPR-mediated cyclic nucleotide signalling.

Authors:  Januka S Athukoralage; Shirley Graham; Christophe Rouillon; Sabine Grüschow; Clarissa M Czekster; Malcolm F White
Journal:  Elife       Date:  2020-04-27       Impact factor: 8.140

9.  Tetramerisation of the CRISPR ring nuclease Crn3/Csx3 facilitates cyclic oligoadenylate cleavage.

Authors:  Januka S Athukoralage; Stuart McQuarrie; Sabine Grüschow; Shirley Graham; Tracey M Gloster; Malcolm F White
Journal:  Elife       Date:  2020-06-29       Impact factor: 8.713

10.  An anti-CRISPR viral ring nuclease subverts type III CRISPR immunity.

Authors:  Januka S Athukoralage; Stephen A McMahon; Changyi Zhang; Sabine Grüschow; Shirley Graham; Mart Krupovic; Rachel J Whitaker; Tracey M Gloster; Malcolm F White
Journal:  Nature       Date:  2020-01-15       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.